Alternatively spliced tissue factor pathway inhibitor: functional implications

Alan E Mast1

  • 1Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI 53201-2178, USA. alan.mast@bcw.edu

Insights

Tissue factor pathway inhibitor (TFPI) regulates blood clotting. Newly identified alternatively spliced TFPI forms exhibit varied cell surface interactions and tissue expression, suggesting distinct physiological roles in coagulation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Hematology

Background:

  • Tissue factor pathway inhibitor (TFPI) is a key regulator of the extrinsic pathway of blood coagulation.
  • TFPI functions as a factor Xa-dependent inhibitor of the tissue factor/factor VIIa complex.
  • The coagulation cascade is a complex system essential for hemostasis.

Purpose of the Study:

  • To investigate the existence and characteristics of alternatively spliced forms of TFPI.
  • To explore the functional implications of these different TFPI variants.
  • To understand the differential expression and cell association mechanisms of TFPI isoforms.

Main Methods:

  • Identification of alternatively spliced transcripts using molecular biology techniques.
  • Analysis of C-terminal regions and cell surface association mechanisms.
  • Differential expression studies in human and mouse tissues.

Main Results:

  • Several alternatively spliced forms of TFPI have been identified.
  • These variants possess distinct C-terminal regions.
  • Differential expression patterns were observed across various tissues.

Conclusions:

  • Alternatively spliced TFPI forms represent a novel layer of coagulation regulation.
  • Variations in C-terminal regions likely influence TFPI localization and function.
  • Distinct tissue expression suggests specialized physiological roles for TFPI isoforms in hemostasis.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...